Sonoma Pharmaceuticals (NASDAQ:SNOA) Issues Earnings Results, Beats Expectations By $0.21 EPS

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.21, FiscalAI reports. Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%. The business had revenue of $6.41 million during the quarter, compared to the consensus estimate of $4.99 million.

Sonoma Pharmaceuticals Stock Up 10.6%

SNOA traded up $0.12 on Thursday, reaching $1.25. 1,508,925 shares of the company traded hands, compared to its average volume of 51,039. Sonoma Pharmaceuticals has a one year low of $0.85 and a one year high of $6.92. The firm has a fifty day simple moving average of $1.17 and a two-hundred day simple moving average of $1.89. The company has a market cap of $5.99 million, a P/E ratio of -0.66 and a beta of 1.28.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC grew its stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 60,977 shares of the company’s stock after acquiring an additional 43,907 shares during the period. DRW Securities LLC owned about 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent quarter. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Sonoma Pharmaceuticals presently has an average rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.